Executive summary

A study by the Samsung group from Korea published in the Green Journal. A total of 103 patients treated with proton therapy including 70 in the PS group and 33 in the PBS group were analyzed.

This study found no significant differences in the rates of overall survival (OS), in-field local control (IFLC), out-field intrahepatic control (OFIHC), extrahepatic progression-free survival (EHPFS), and complete response (CR) between the matched groups. There is no significant difference in the toxicity profiles between PS and PBS PBT for primary HCC.
 

Top cancer treatments